[{"uuid": "b37f00c5-1c76-3ab3-87f0-f48c642cbb06", "title": "Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cytokinetics-announces-recipients-seventh-annual-123000947.html", "providerPublishTime": 1738240200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/DZFRNHN4_QNaOOJqev_V_w--~B/aD0xMzE7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8745ef5113d19aee1cb683657b22ff4", "width": 300, "height": 131, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/fniiHyCCUagKujyuPkMu0A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d8745ef5113d19aee1cb683657b22ff4", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CYTK"]}, {"uuid": "afe17d22-d20c-3927-9cfd-3ddbf8007209", "title": "The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-sage-145500682.html", "providerPublishTime": 1738248900, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/H5j0X5VJ3peIo6cA0ud3Qg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BIIB", "SAGE", "AKRO", "CYTK"]}, {"uuid": "6640d076-c220-3617-aab9-38b207590a8b", "title": "Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/biotech-stock-roundup-sage-declining-170200168.html", "providerPublishTime": 1738170120, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/GGbbFeHcXoThOctYgnQqXQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["SAGE", "BIIB", "CYTK", "AKRO"]}, {"uuid": "fcbf1b25-55af-3b96-95a5-d92ded1ffa79", "title": "What Are Analysts Talking About Cytokinetics (CYTK)?", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/analysts-talking-cytokinetics-cytk-215038132.html", "providerPublishTime": 1738014638, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/y0b05Soo75FYrVYRgxYyAg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/5348e66e2702f72d99a644e7ea290dc2", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ffF71SnWf4sL2Uua_KCa.w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/5348e66e2702f72d99a644e7ea290dc2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CYTK"]}, {"uuid": "cb240420-1aab-3f62-8acc-2fe4c7579dc7", "title": "CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/cytk-stock-rises-enrollment-begins-161900028.html", "providerPublishTime": 1737649140, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/46gFT4Y7HZuuo2Xj6ImXmw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/35df2d293bff824e6b9f2134b8f740a3", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/VuDbIK23jerGm8ofHmy3sQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/35df2d293bff824e6b9f2134b8f740a3", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CYTK"]}, {"uuid": "c7585678-96db-3bbd-8b7e-c45cf310b2f8", "title": "Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst", "publisher": "Benzinga", "link": "https://finance.yahoo.com/news/cytokinetics-heart-drugs-future-sparks-204350038.html", "providerPublishTime": 1737578630, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/vQ1APkgtDjnhV6f7vslfIQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/9b14f2f4d3661fb044111c987b169c93", "width": 983, "height": 553, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/pN0klSnxI1.fWbwfbzEPAg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/9b14f2f4d3661fb044111c987b169c93", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CYTK"]}, {"uuid": "7e5b30c3-c029-3459-87c9-28261d530c5e", "title": "Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cytokinetics-announces-start-amber-hfpef-123000701.html", "providerPublishTime": 1737462600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/DZFRNHN4_QNaOOJqev_V_w--~B/aD0xMzE7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8745ef5113d19aee1cb683657b22ff4", "width": 300, "height": 131, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/fniiHyCCUagKujyuPkMu0A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d8745ef5113d19aee1cb683657b22ff4", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CYTK"]}, {"uuid": "2f59d08e-d5c9-37e6-8a8d-14bebc584325", "title": "Netflix upgraded, Reddit downgraded: Wall Street's top analyst calls", "publisher": "The Fly", "link": "https://finance.yahoo.com/news/netflix-upgraded-reddit-downgraded-wall-143609107.html", "providerPublishTime": 1737556569, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/zUit8GQVW5kcaTZHEPMI9Q--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec", "width": 1200, "height": 628, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/IPH9wCP.ftudEFOX7xr1MA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["NFLX", "RDDT"]}, {"uuid": "c962cca7-29c1-36a3-8237-06b6dc31252a", "title": "Cytokinetics Announces 2025 Corporate Milestones and Vision 2030", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cytokinetics-announces-2025-corporate-milestones-123000288.html", "providerPublishTime": 1736771400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/DZFRNHN4_QNaOOJqev_V_w--~B/aD0xMzE7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8745ef5113d19aee1cb683657b22ff4", "width": 300, "height": 131, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/fniiHyCCUagKujyuPkMu0A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d8745ef5113d19aee1cb683657b22ff4", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CYTK"]}, {"uuid": "2a9d4018-7cdb-3476-bbfc-f7905e12c1a1", "title": "Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cytokinetics-present-43rd-annual-j-210000224.html", "providerPublishTime": 1736197200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/DZFRNHN4_QNaOOJqev_V_w--~B/aD0xMzE7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8745ef5113d19aee1cb683657b22ff4", "width": 300, "height": 131, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/fniiHyCCUagKujyuPkMu0A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d8745ef5113d19aee1cb683657b22ff4", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CYTK"]}, {"uuid": "4b22b336-97f1-37b5-a660-6ae58dc4ae0d", "title": "Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cytokinetics-announces-inducement-grants-under-210000379.html", "providerPublishTime": 1735938000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/DZFRNHN4_QNaOOJqev_V_w--~B/aD0xMzE7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8745ef5113d19aee1cb683657b22ff4", "width": 300, "height": 131, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/fniiHyCCUagKujyuPkMu0A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d8745ef5113d19aee1cb683657b22ff4", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CYTK"]}, {"uuid": "ad564114-05e7-3cf1-9d83-e1159014c2bb", "title": "Cytokinetics Says European Regulator Validated its Application for Cardiomyopathy Drug Candidate", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/cytokinetics-says-european-regulator-validated-130356254.html", "providerPublishTime": 1734959036, "type": "STORY", "relatedTickers": ["CYTK"]}, {"uuid": "70aff249-6298-372d-8f7f-5e10c296d87e", "title": "Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/cytokinetics-says-sanofi-acquiring-rights-085816527.html", "providerPublishTime": 1734685096, "type": "STORY", "relatedTickers": ["CYTK", "SNY"]}, {"uuid": "66e02483-89f3-3b3b-96b0-14945bdaff58", "title": "Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cytokinetics-announces-european-medicines-agency-123000947.html", "providerPublishTime": 1734957000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/DZFRNHN4_QNaOOJqev_V_w--~B/aD0xMzE7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8745ef5113d19aee1cb683657b22ff4", "width": 300, "height": 131, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/fniiHyCCUagKujyuPkMu0A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d8745ef5113d19aee1cb683657b22ff4", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CYTK"]}, {"uuid": "e597d9ec-01ba-316e-847d-fcbc7c82ff22", "title": "Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/why-cytokinetics-cytk-down-9-163115947.html", "providerPublishTime": 1733502675, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/0K2vxHTAGj_tGrBqjPJ8Cg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1", "width": 900, "height": 600, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/XoWe2u8bPKAKGhfRjcBBFA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/f889276f4a638f3c7a79c0e3e6b768c1", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CYTK", "INSM"]}, {"uuid": "ad3ea12c-92fe-33a4-9e80-6b5eec0e9f60", "title": "RBC Raises Price Target on Cytokinetics to $82 From $80, Keeps Outperform, Speculative Risk", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/rbc-raises-price-target-cytokinetics-123555194.html", "providerPublishTime": 1734525355, "type": "STORY", "relatedTickers": ["CYTK"]}, {"uuid": "64903547-fec1-3496-9ebb-60ec735e548b", "title": "Cytokinetics Initiates Confirmatory Study on Heart Failure Drug", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/cytokinetics-initiates-confirmatory-study-heart-173000642.html", "providerPublishTime": 1733333400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/GGbbFeHcXoThOctYgnQqXQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CYTK"]}, {"uuid": "708e3b9b-e8c8-388c-bc9a-e83124aa79aa", "title": "FDA Accepts Cytokinetics' Application for Cardiovascular Drug", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/fda-accepts-cytokinetics-application-cardiovascular-183700233.html", "providerPublishTime": 1733251020, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/vZlajmbYZzKfSC9h66RaJg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/hnOApu9CDRGb8c2leW0aaA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CYTK", "BAYN.DE"]}, {"uuid": "7489378a-faf0-3142-91e9-0ca7722d94ec", "title": "Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/cytokinetics-cytk-reports-q3-loss-220502659.html", "providerPublishTime": 1730930702, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/M2z0wFqvnPw7eaLU0tPuyQ--~B/aD02MzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85", "width": 900, "height": 636, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ml_IW6uskjsyNFznUfnUDA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CYTK"]}, {"uuid": "fcd2bab2-bc75-38b4-aa60-e59d4be58750", "title": "Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/cytokinetics-announces-sanofi-acquired-rights-050000984.html", "providerPublishTime": 1734670800, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/DZFRNHN4_QNaOOJqev_V_w--~B/aD0xMzE7dz0zMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d8745ef5113d19aee1cb683657b22ff4", "width": 300, "height": 131, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/fniiHyCCUagKujyuPkMu0A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d8745ef5113d19aee1cb683657b22ff4", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CYTK"]}]